Abstract
Background: Age-related macular degeneration (AMD) is a condition that accounts for 75% of cases of legal blindness in individuals over the age of 50. Objectives: The objective of this review has been to evaluate the clinical effectiveness of available combined treatments modalities in the treatment of neovascular AMD. Data Sources: Central and Medline were searched for original research studies (Phase I, II, III), abstracts, and review articles concerning combination therapies for the control of neovascular AMD. We included randomized controlled trials (RCTs). Results: The results of therapeutic trials focused on the actual options in the management of neovascular AMD are discussed. Intravitreal treatment with substances targeting all isotypes of vascular endothelial growth factor (VEGF) results in a significant increase in visual acuity in patients with neovascular AMD. The combination with occlusive therapies like verteporfin photodynamic therapy (V-PDT) potentially offers a reduction of re-treatment frequency rate and long-term maintenance of the benefit reached. Despite the promise from combining anti-VEGF therapies with V-PDT, other combinations to improve outcomes with V-PDT deserve attention. Corticosteroids demonstrated an antiangiogenic effect and targeted the extravascular components of CNV, such as inflammatory cells and fibrocytes. Nevertheless, the study on the clinical application of corticosteroids will require a better understanding of the potential complications. Further developments interacting with various steps in the angiogenic cascade are under clinical or preclinical evaluation and may soon become available. In AMD the goal of a combination regimen is to address the therapy toward neovascular, inflammatory, and proliferative components of the disease. Conclusions: Combined treatments strategies are an obvious step providing disease control when it is not achieved with a single therapeutic approach. One risk of using a single therapy to control AMD is a rebound induced by compensatory stimulation of other pathogenetic pathways. Combination therapy is a logical approach to address mechanisms of disease progression that appear to be self-sustaining once initiated.
Keywords: Choroidal neovascularisation (CNV), age related macular degeneration (AMD), retinal degeneration, vascular endothelial growth factor (VEGF), verteporfin photodynamic therapy (V-PDT), anti-angiogenic therapies, combined therapies, isotypes, visual acuity, occlusive therapies, Corticosteroids, inflammatory cells, fibrocytes, Ranibizumab, bevacizumab, pegaptanib, stroke, myocardial infarction, MARINA, ANCHOR, immunosuppressants, rapamycin, hypoxia, steroids, attenuation
Current Drug Targets
Title: Combined Treatment Modalities for Age Related Macular Degeneration
Volume: 12 Issue: 2
Author(s): R. A. Das, A. Romano, F. Chiosi, M. Menzione and M. Rinaldi
Affiliation:
Keywords: Choroidal neovascularisation (CNV), age related macular degeneration (AMD), retinal degeneration, vascular endothelial growth factor (VEGF), verteporfin photodynamic therapy (V-PDT), anti-angiogenic therapies, combined therapies, isotypes, visual acuity, occlusive therapies, Corticosteroids, inflammatory cells, fibrocytes, Ranibizumab, bevacizumab, pegaptanib, stroke, myocardial infarction, MARINA, ANCHOR, immunosuppressants, rapamycin, hypoxia, steroids, attenuation
Abstract: Background: Age-related macular degeneration (AMD) is a condition that accounts for 75% of cases of legal blindness in individuals over the age of 50. Objectives: The objective of this review has been to evaluate the clinical effectiveness of available combined treatments modalities in the treatment of neovascular AMD. Data Sources: Central and Medline were searched for original research studies (Phase I, II, III), abstracts, and review articles concerning combination therapies for the control of neovascular AMD. We included randomized controlled trials (RCTs). Results: The results of therapeutic trials focused on the actual options in the management of neovascular AMD are discussed. Intravitreal treatment with substances targeting all isotypes of vascular endothelial growth factor (VEGF) results in a significant increase in visual acuity in patients with neovascular AMD. The combination with occlusive therapies like verteporfin photodynamic therapy (V-PDT) potentially offers a reduction of re-treatment frequency rate and long-term maintenance of the benefit reached. Despite the promise from combining anti-VEGF therapies with V-PDT, other combinations to improve outcomes with V-PDT deserve attention. Corticosteroids demonstrated an antiangiogenic effect and targeted the extravascular components of CNV, such as inflammatory cells and fibrocytes. Nevertheless, the study on the clinical application of corticosteroids will require a better understanding of the potential complications. Further developments interacting with various steps in the angiogenic cascade are under clinical or preclinical evaluation and may soon become available. In AMD the goal of a combination regimen is to address the therapy toward neovascular, inflammatory, and proliferative components of the disease. Conclusions: Combined treatments strategies are an obvious step providing disease control when it is not achieved with a single therapeutic approach. One risk of using a single therapy to control AMD is a rebound induced by compensatory stimulation of other pathogenetic pathways. Combination therapy is a logical approach to address mechanisms of disease progression that appear to be self-sustaining once initiated.
Export Options
About this article
Cite this article as:
A. Das R., Romano A., Chiosi F., Menzione M. and Rinaldi M., Combined Treatment Modalities for Age Related Macular Degeneration, Current Drug Targets 2011; 12 (2) . https://dx.doi.org/10.2174/138945011794182719
DOI https://dx.doi.org/10.2174/138945011794182719 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antegrade Techniques for Chronic Total Occlusions
Current Cardiology Reviews Editorial [PET and SPECT in Drug Evaluation and Drug Design: Novel Techniques]
Current Pharmaceutical Design Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease
Current Genomics The Concept of “Neuroprotection” in Neurological Diseases
Current Neuropharmacology Arterial Stiffness in Haemodialyzed Patients: Findings and Controversies
Current Hypertension Reviews Cardiovascular Complications of HIV Infection and Treatment
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiac Response to Exercise in Normal Ageing: What Can We Learn from Masters Athletes?
Current Cardiology Reviews Perioperative Handling of Antiplatelet Drugs. A Critical Appraisal
Current Drug Targets The Use of Carvedilol in Pediatric Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets The Effect of Positive Mental Imagery on Labor Pain Tolerance in Primiparous Women Referred to Atieh Hospital of Hamadan, Iran, 2018: A Randomized Controlled Clinical Trial Study
Current Women`s Health Reviews Effects of Imidazolic Agonism on Blood Pressure, Sympathetic Activity, Left Ventricular Hypertrophy and Insulin Resistance
Current Hypertension Reviews Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management
Current Vascular Pharmacology Role of Copper in Angiogenesis and Its Medicinal Implications
Current Medicinal Chemistry Extracellular ATP and Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders Uremia, Atherothrombosis and Malnutrition: The Role of L-arginine- Nitric Oxide Pathway
Cardiovascular & Hematological Disorders-Drug Targets Development, Validation, and Application of a High-Performance Liquid Chromatography Method for the Analysis of Dissolution Samples of Telmisartan and Rosuvastatin Calcium Double-Layer Formulation
Current Pharmaceutical Analysis Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds Regulation of the Sodium-Phosphate Cotransporter Pit-1 and its Role in Vascular Calcification
Current Vascular Pharmacology Exogenous Progesterone: A Potential Therapeutic Candidate in CNS Injury and Neurodegeneration
Current Medicinal Chemistry Could Additional Inhibitors of the Renin -Angiotensin System be Clinically Useful?
Current Hypertension Reviews